KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Inventory (2016 - 2025)

Jazz Pharmaceuticals has reported Inventory over the past 16 years, most recently at $417.0 million for Q4 2025.

  • Quarterly Inventory fell 13.21% to $417.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $417.0 million through Dec 2025, down 13.21% year-over-year, with the annual reading at $417.0 million for FY2025, 13.21% down from the prior year.
  • Inventory was $417.0 million for Q4 2025 at Jazz Pharmaceuticals, down from $483.1 million in the prior quarter.
  • Over five years, Inventory peaked at $1.3 billion in Q2 2021 and troughed at $115.5 million in Q1 2021.
  • The 5-year median for Inventory is $604.4 million (2023), against an average of $672.2 million.
  • Biggest five-year swings in Inventory: surged 1252.22% in 2021 and later crashed 36.01% in 2022.
  • Tracing JAZZ's Inventory over 5 years: stood at $1.1 billion in 2021, then plummeted by 33.43% to $714.1 million in 2022, then dropped by 16.39% to $597.0 million in 2023, then fell by 19.53% to $480.4 million in 2024, then fell by 13.21% to $417.0 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $417.0 million, $483.1 million, and $505.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.